Chapter Social Rocks at Annual Meeting!

Posted by Kevin Chronley
On November 14, 2018

Now an Annual Meeting tradition, our Boston Area Social at the Hard Rock Cafe on Monday evening was a fantastic event and productive opportunity to build relationships. This was not solely due to the Most Significant “Stand-Up” Moment presented by Chapter Past Presidents John Spohn and Jack Campion, which featured a historical poem reading by […]

ISPE Annual Meeting Hits the Mark in Philly

Posted by Kevin Chronley
On November 13, 2018

Along with over 115 attendees from the Boston Area Chapter, I had the opportunity to join the vast array of participants who traveled to Philly for the 2018 ISPE Annual Meeting & Expo November 4-7. The meeting far exceeded my expectations. It was a fun opportunity to build relationships ‒ some old ones strengthened and […]

Tango Therapeutics and Gilead Sciences to Collaborate on Immuno-Oncology

Posted by ISPE Boston
On November 12, 2018

Cambridge-based Tango Therapeutics, a company focused on the discovery and development of novel cancer therapies, has announced a global strategic collaboration with Gilead Sciences to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer. Under the multi-year collaboration, Tango will perform target discovery and validation and Gilead will have […]

Chapter Member Anniversaries: October 2018

Posted by ISPE Boston
On November 8, 2018

Please congratulate the following members celebrating milestone anniversaries in October 2018. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Dr. Michael T. Ku, PharmD, MBA, Pfizer Inc John S. Magyar, Parsons Infrastructure & Technology Ric Feldt, Jeff Smith & Associates Stephen R. Higham, PE, Sanofi Peter […]

Welcome New Members!

Posted by ISPE Boston
On November 8, 2018

We would like to introduce the Members who joined ISPE in October 2018, welcome them to the Chapter and encourage them (and all of our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And […]

GO Therapeutics Inks Deal with Roche

Posted by ISPE Boston
On November 1, 2018

Cambridge-based GO Therapeutics, a company applying new advances in glycoproteomics to develop antibody-based cancer therapeutics, announced in early October that it has entered into a license agreement with Roche. The agreement grants Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target. Under the terms of the agreement, Roche will pay […]

Paratek Wins FDA Approval of “Modernized” Tetracycline

Posted by ISPE Boston
On November 1, 2018

Boston-based Paratek Pharmaceuticals has announced that the FDA has approved Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). Nuzyra, a modernized tetracycline, is a once-daily IV and oral antibiotic that exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and drug […]

Alexion on the Move with Acquisition & Collaboration

Posted by ISPE Boston
On October 30, 2018

Alexion, newly headquartered in Boston’s Seaport District after its move from New Haven, announced in late September that it is acquiring Syntimmune, a clinical-stage biotech developing antibody therapeutics targeting the neonatal Fc receptor (FcRn). Syntimmune’s SYNT001 – a humanized monoclonal antibody that inhibits the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes […]

Stoke Therapeutics Raises $90M to Advance Novel Oligonucleotide Medicines

Posted by ISPE Boston
On October 25, 2018

Bedford-based Stoke Therapeutics has announced it has completed a $90 million Series B financing to advance its pipeline of antisense oligonucleotide medicines for Dravet Syndrome and other severe genetic diseases. Stoke, which launched in 2018 with a $40 million Series A investment, has identified thousands of genes that could be addressed by its proprietary TANGO […]

Takeda Signs $50M Deal with Enterome for Crohn’s Disease Treatment

Posted by ISPE Boston
On October 25, 2018

Enterome, a clinical-stage French biotech with its U.S. headquarters in Cambridge, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical. Enterome is developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer. The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, […]

Page 89 of 116«‹87 888990 91 ›»